Second National Workshop on Personalised Cancer Medicine

Date: November 17, 2017, 9.00 – 16.00

Venue: Nobel Forum, Nobels väg 1, Karolinska Institutet, Solna

The PCM Program is happy to announce the Second National Workshop on Personalised Cancer Medicine! Speakers from all major cancer centers in Sweden have been invited together with international guests and industry representatives to discuss the recent advancements in Personalised/Precision Medicine and the future of Cancer Health Care. The primary focus is to share research results and experiences from the different sites and discuss challenges and opportunities for the future. You Are Welcome! If you are interested please contact the PCM program coordinator: michele.masucci@ki.se.

National workshop on Personalised/Precision Cancer Medicine (PCM)

Date: November 17 2017, 9.00 – 16.00

Venue: Nobel Forum, Nobels väg 1, Karolinska Institutet, Solna

9.00 Ingemar Ernberg, Claes Karlsson, Stockholm Welcome note

9.10 (-9.22) Sonja Eaker Fält, Uppsala Strengthening the biobank infrastructure in Sweden for the benefit of health care, research and patients

9.25 (-9.37) Richard Rosenquist, Stockholm Genomic Medicine Sweden

9.40 (-9.52) Beatrice Melin, Umeå SWElife: Supporting the development of PCM

9.55 (-10.07) Klas Kärre, Stockholm The Swedish Cancer Society: PCM research funding

10.10 (-10.22) Tobias Sjöblom, Uppsala The Sjöberg Foundation: Focus on PCM

10.25 Coffee

10.45 (-10.57) Mikael Johansson, Umeå Precision medicine in lung cancer

11.00 (-11.12) Matthias Löhr, Stockholm Pancreatic cancer as an example for PCM

11.15 (-11.27) Claes Andersson, Uppsala Ex vivo drug testing for PCM

11.30 (-12.05) Hanno Glimm, Heidelberg The NCT-MASTER workflow and experiences

12.10-13.00 Lunch

13.00 (-13.12) Ruth Palmer, Göteborg ALK-driven cancer

13.15 (-13.27) Anders Ståhlberg, Göteborg Early cancer diagnostics, treatment monitoring and detection of therapy resistance using ultrasensitive mutation analysis in liquid biopsies

13.30 (-13.42) Lisa Ryden, Lund Circulating tumor cells as a surrogate marker in clinical trials: Myth or reality?

13.45 (-13.57) Hanna Eriksson, Stockholm Liquid biopses for biomarker identification in cutaneous malignant melanoma

14.00 (-14.12) Mattias Belting, Lund Extracellular vesicles in cancer

14.15 (-14.27) Lennart Blomqvist, Stockholm   Cancer imaging: Focus on PCM

14.30 -14.50 Coffee

14.50 (- 15.25) Gerrit Meijer, Amsterdam   Improving the translational research process through informatics tools: The Dutch experience

 

15.30 (-16.05) Jordi Rodon, Houston   PCM: Early clinical trials  

16.10-16.30 Concluding remarks & Next meeting